FDA Approves Easy-To-Use Naloxone: Antidote to Zohydro?
This article was originally published in RPM Report
FDA’s recent approval of an auto-injection form of naloxone may be an opportunity to change the public perception of the agency’s priorities in the opioid and prescription drug abuse debate.
You may also be interested in...
FDA approved Zogenix’ single-entity hydrocodone product following a negative advisory committee meeting, and is facing ongoing opposition as the drug’s launch begins. The agency argues the risk is consistent with other extended-release opioids – and abuse-deterrent technology is too new to require.
A House hearing on prescription abuse highlighted a potential OTC switch: naloxone for opioid overdose.
New ‘statement of policy’ directs US FDA to publish charts of its approval timeliness – using an outdated 180-day benchmark to make its approval speed look worse.